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Abstract
Proliferation of the pathogenic Plasmodium asexual blood stages in host erythrocytes requires an exquisite capacity to
protect the malaria parasite against oxidative stress. This function is achieved by a complex antioxidant defence system
composed of redox-active proteins and low MW antioxidants. Here, we disrupted the P. berghei plasmoredoxin gene that
encodes a parasite-specific 22 kDa member of the thioredoxin superfamily. The successful generation of plasmoredoxin
knockout mutants in the rodent model malaria parasite and phenotypic analysis during life cycle progression revealed a
non-vital role in vivo. Our findings suggest that plasmoredoxin fulfils a specialized and dispensable role for Plasmodium and
highlights the need for target validation to inform drug development strategies.
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Introduction
Plasmodium, the etiologic agent of malaria, is a unicellular
facultative intracellular parasite of the phylum Apicomplexa.A
hallmark of the malaria parasite is its remarkable capacity to
specifically invade and replicate inside red blood cells. This
intraerythrocytic proliferation phase ultimately leads to the disease
known as malaria. Due to the high metabolic rates of the rapidly
growing and multiplying parasite, large quantities of toxic redox-
active by-products are generated. Additional reactive oxygen and
nitrogen species are generated by immune effector cells of the host
in response to parasite infection and during hemoglobin
degradation in the food vacuole of the parasite. Therefore, inside
erythrocytes, the ability of Plasmodium to defend itself against
oxidative damage is of vital importance for parasite survival [1,2],
and it appears to be highly effective in this respect [3]. Plasmodium
employs multiple biochemical pathways that mediate antioxidant
defense and redox-regulation and play a central role in
pathogenesis [4–9].
In most eukaryotic organisms, redox-active enzymes, such as
catalase, superoxide dismutase, and peroxidases as well as an
enzymatic cascade that generates reduced electron donors, i.e.
glutathione (GSH) and thioredoxin (Trx), sustain the cellular redox
homeostasis [10]. This redox network is split into two major arms,
the GSH and the Trx system, that serve complementary functions
in antioxidant defense and DNA synthesis. Interestingly, the
malarial parasite Plasmodium lacks two central antioxidant
enzymes: (i) catalase that typically detoxifies hydrogen peroxide
and (ii) a classical glutathione peroxidase, a selenoenyzme that
reduces lipid hydroperoxides to their alcohols [9]. This apparent
deficiency further underscores the central importance of the
thioredoxin system in the parasite. In good agreement, Trx
reductase, which transfers electrons from NADPH to Trx, appears
to perform vital functions for asexual development of the malaria
parasite in vitro and is considered an attractive target for
antimalarial drug development [11].
Intriguingly, malaria parasites possess-in addition to the classical
thioredoxins-a Plasmodium-specific member of the thioredoxin
superfamily termed plasmoredoxin (Plrx) (P. falciparum GenBank
AAF87222) [12]. Plrx is a 22 kDa dithiol protein with the unique
active site sequence WCKYC. Plrx is not reduced by thioredoxin
reductase but can react with glutaredoxin and glutathione.
Although a non-enzymatic reaction between reduced Trx and
glutathione disulfide (GSSG) has been described in insects, which
lack glutathione reductase [13], the physiologic electron donor for
P. falciparum plasmoredoxin still remains to be identified. As
described for certain thioredoxins and glutaredoxins, Plrx has been
shown to serve as electron donor for ribonucleotide reductase.
Furthermore, the protein is capable of reducing disulfide bonds in
general and in particular P. falciparum thioredoxin peroxidase 1,
the major cytosolic peroxiredoxin of the parasite [12,14].
In this study, we addressed the cellular role of Plrx in the rodent
malaria model parasite Plasmodium berghei. Targeted gene disrup-
tion permits drug target validation or elucidation of the in vivo role
of the gene product. The corresponding predicted experimental
outcomes are refractoriness to gene targeting, which would
correlate with a vital role in asexual blood stage development, or
a detectable phenotype during life cycle progression, respectively.
Because of the potential to design tailor-made inhibitors of the
Plasmodium redox network as innovative antimalarial drugs [4,5],
target validation of individual redox-active enzymes paves the way
for future drug discovery approaches. Our findings that loss of Plrx
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2474function does not affect parasite development under normal
growth conditions exemplifies the important role of reverse
genetics in guiding drug development against malaria.
Results
Generation of Plrx(-) parasites
To test whether plasmoredoxin is important for asexual
replication of P. berghei, we first targeted the PbPlrx gene with an
integration vector that disrupts the gene locus via a single cross
over event. After a single transfection we successfully integrated
the disruption plasmid (data not shown). To confirm our
unexpected finding that PbPlrx can be disrupted we constructed
a replacement vector containing the PbPlrx 59 and 39 UTRs that
flank the positive selectable marker, which confers resistance to the
antifolate pyrimethamine (Fig. 1A). Upon a double cross over
event this vector is predicted to disrupt the entire PbPlrx open
reading frame (ORF). After continuous selection with oral
pyrimethamine a resistant population was obtained and genotyped
(data not shown). This parental parasite population contained the
correct integration mixed with WT parasites and was used for
cloning of four independent parasite Plrx-deficient lines, named
Plrx(-)Rep. Replacement-specific PCR analysis verified the correct
replacement event after homologous recombination (Fig. 1B). To
confirm the absence of Plrx transcripts in Plrx(-) parasites, RT-
PCR and subsequent cDNA synthesis was performed with
poly(A)+ RNA from mixed blood stages (Fig. 1C). In good
agreement with the previous expression profiling of PfPlrx [12], we
detected the PbPlrx transcript in asexual blood stage parasites of
the WT. As predicted, no Plrx transcripts were detected in the
knockout parasite lines. Moreover, Western blot analysis of Plrx(-)
blood stages with a PbPlrx-specific anti-peptide antiserum
confirmed complete absence of the protein in Plrx(-) parasites
(Fig. 1D). Together, the successful generation of Plrx-deficient
parasites demonstrates that this gene is not essential for
proliferation of the asexual blood stages.
Plrx is dispensable for in vivo and in vitro growth of
asexual blood stages
To test whether Plrx serves an auxiliary role during blood stage
growth we first performed an in vivo growth assay by intravenous
injection of 1,000 asexual parasites, followed by parasitemia counts
every 12 hours post infection (Fig. 2A). Notably, proliferation of
Figure 1. Targeted deletion ofthe P. berghei plasmoredoxin gene. (A) Replacement strategy for targeted gene disruption of PbPlrx. The wild-type
Plrx locus (WT) is targeted with a KpnI( K ) /SacII (S)-linearized replacement plasmid (pPlrxRep) containing the 59and 39UTR of PbPlrx and the positive
selection marker TgDHFR-TS. After double cross over homologous recombination, the Plrx open reading frame is substituted by the selection marker,
resultinginthemutantPlrx(-)allele.Replacement-andWT-specifictestprimercombinationsandexpectedfragmentsareshownas lines.(B)Replacement-
specific PCR analysis. Confirmation of the predicted gene targeting is done by primer combinations that only amplify a signal in the recombinant locus
(test). The absence of a WT-specific signal in the clonal Plrx(-) population confirms the purity of the mutant parasite line. (C) Depletion of Plrx transcripts in
Plrx(-) parasites. cDNA from WT and Plrx(-) blood stages was used as template for Plrx-specific PCR reactions (upper panel). Amplification of glutathione
reductase (GR) transcripts was used as a positive control (lower panel). (D) Western blot analysis of WT and Plrx(-) blood stages. Extracts from WT or Plrx(-)
(16 mg total protein each)were separated ona 15% SDS gel and probed withthe polyclonal anti-Plrx serum (upper panel) or a polyclonal anti-actinserum
(lower panel). As a positive control 160 ng recombinantly expressed P. berghei plasmoredoxin (protein) was added.
doi:10.1371/journal.pone.0002474.g001
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ing that Plrx is dispensable for the parasite under normal growth
conditions. We next wanted to determine whether loss of Plrx
function affects parasite growth under redox stress conditions. To
this end, we performed an in vitro culture assay over 24 hours to
determine the IC50 values in WT and Plrx(-) parasites upon
exposure to antimalarial drugs, some of which act also as elicitors
of redox stress [15]. The compounds tested included 4-aminoqui-
nolines, i.e. chloroquine and amodiaquine, the first synthetic
antimalarial agent methylene blue, mefloquine, and the central
compound of artemisin-combination therapies (ACT) recom-
mended as first-line antimalarial treatment, artemisinin. In order
to minimize stage-specific effects we used non-synchronized
asexual blood stages [16]. Notably, the IC50 values of the Plrx(-)
parasite line did not differ significantly from WT parasites,
excluding, at least ex vivo, a central function of Plrx in anti-redox
stress defense (Table 1).
To elucidate whether this dispensability can be observed in vivo
we applied a growth assay as outlined above under enhanced
oxidative stress conditions. We selected methylene blue (MB) as
this antimalarial was shown to challenge the parasites intracellular
reducing milieu through the generation of pro-oxidant H2O2 [17].
The WT and Plrx(-) infected mice were treated orally with 50 mg/
kg body weight methylene blue as previous dose finding
experiments revealed rapid elimination of WT parasites with
100 mg/kg body weight MB (data not shown). Even with
enhanced oxidative stress in vivo Plrx-deficient parasites grow
indistinguishable from WT parasites (Fig. 2B), excluding a central
role of P. berghei Plrx in antioxidant defense.
Depletion of Plrx induces only weak changes of transcript
levels of selected redox proteins
Since our in vitro and in vivo data exclude an essential function of
Plrx to maintain the parasite’s redox equilibrium, we extended our
analysis of the Plrx-deficient strain to expression profiling of
selected redox proteins. This analysis was expected to further
reveal the modulation of intracellular redox networks. We studied
the effects of the Plrx-deletion on mRNA levels of genes related to
cellular redox metabolism with a focus on the cytosolic
components because Plrx is a cytosolic member of the antioxidant
network [12]. Gene transcript levels were measured by quantita-
tive real-time RT-PCR and the effect on a target gene is reported
as differences in comparison to a WT control population (Fig. 3).
Transcript levels of mRNA for the two major sustainers of redox
homeostasis, thioredoxin reductase (TrxR) and glutathione reduc-
tase (GR) increased only slightly. Plrx was previously shown to
directly interact with these two systems [12], thereby potentially
acting as an additional antioxidant defence line of Plasmodium.
The prediction was that deletion of Plrx may be accompanied by a
compensatory upregulation of functional paralogues that balance
the reducing capacity of Plrx. Such a function can most likely be
fulfilled by thioredoxin (Trx) and/or glutathione (GSH). While this
assumption is supported by the weak increase of Trx mRNA levels,
GSH cannot be tested directly because it is only a tripeptide.
Another member of the thioredoxin superfamily, glutaredoxin
(Grx) did not change significantly. Moreover, Plrx-deficient
parasites show a slight decrease in mRNA levels of thioredoxin
peroxidase 1 (TPx1), the major cytosolic peroxiredoxin of the
parasite, and ribonucleotide reductase (RiboR). Collectively, these
data show that depletion of PbPlrx caused only weak alterations in
gene expression of selected members of the cytosolic redox
network compared to wild type parasites.
Figure 2. Replication of asexual blood stage parasites is unaffected in Plrx(-) mutant parasites. (A) In vivo growth curves of WT and Plrx(-)
parasites. Five and six naı ¨ve animals were injected intravenously with 1,000 WT and Plrx(-) parasites, respectively. Parasitemia was determined every
12 hours after infection by microscopic examination of Giemsa-stained blood smears. (B) In vivo growth curves of WT and Plrx(-) parasites under
constant exposure of methylene blue (50 mg/kg body weight). Treatment started immediately after infection with 1,000 WT and Plrx(-) parasites,
respectively.
doi:10.1371/journal.pone.0002474.g002
Table 1. In vitro characterization of P. berghei blood stages
(IC50 data) [nM]
Drug WT Plrx(-)
Chloroquine 35.7 (612.5) 33.4 (66.3)
Methylene blue 50.6 (69.6) 55 (610.5)
Artemisinin 87.1 (64.6) 79.2 (623.5)
Mefloquine 50.1 (621.1) 41.5 (610.4)
Amodiaquine 20.5 (610.4) 19.2 (69.6)
doi:10.1371/journal.pone.0002474.t001
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cycle.
Since we could exclude a discernible function of Plrx in blood
stage development we extended our phenotypic analysis to the
entire Plasmodium life cycle (Table 2). Plrx(-) parasites did not differ
from WT parasites in sexual development, which is a prerequisite
for transmission to mosquitoes (data not shown). Dissection of
infected mosquitoes showed similar numbers of oocysts, midgut-
associated and salivary gland-associated sporozoites in WT and
Plrx deficient parasites (Table 2). Therefore, Plrx is also
dispensable for sporogony and sporozoite maturation. When
mature salivary gland sporozoites were tested for infectivity to the
mammalian host in vivo and in vitro again no phenotypic differences
between the two parasite lines could be observed. Hepatocytes
infected with Plrx(-) sporozoites were indistinguishable from WT
infected cells and produced high numbers of mature liver stage
parasites (Table 2). When tested in vivo by intravenous injection or
natural mosquito bite the recipient animals became patent after
similar prepatent periods compared to WT sporozoite inoculation
(Table 2). Together these data exclude a vital role for Plrx in
Plasmodium life cycle progression under standard conditions.
Discussion
We initiated this study to test the potential of plasmoredoxin
(Plrx), a Plasmodium specific member of the thioredoxin superfamily
[12], as a novel antimalarial drug target. Using classical reverse
genetics we could demonstrate that Plrx is dispensable for
Plasmodium development inside its host cells. This finding rejects
future drug discovery efforts that aim at specifically targeting Plrx,
most likely even in combination with existing antimalarial drugs.
Successful generation of Plrx(-) mutants permitted a detailed
observation of the in vivo function of Plrx during life cycle
progression of the malaria parasite. Again, no vital role at any
stage of the parasite life cycle was revealed. Therefore, specific
targeting of plasmoredoxin is not suitable either for transmission-
blocking or causal-prophylactic malaria intervention strategies.
The redox-active proteins thioredoxin and glutaredoxin are
founding members of the thioredoxin superfamily. Additional
members include tryparedoxin of Trypanosomes, the protein disulfide
isomerase and a few bacterial disulfide bondforming proteins. This
group of proteins carries out oxidation and reduction reactions
based on the chemistry of the catalytic cysteine residues. The
unifying features of all family members are (i) the typical active site
motif C-X-X-C and (ii) similarity in the overall tertiary protein
structure, the so-called thioredoxin fold, despite low overall amino
acid sequence similarity [18]. Intriguingly, homozygous deletions
of the mouse cytoplasmic Trx1 or the mitochondrial isoform Trx2
resulted in early embryonic lethality indicating key roles of the
thioredoxin system in the development of multicellular organisms
[19,20]. In analogy, the recent characterization of the Plasmodium-
specific dithiol:disulfide oxidoreductase Plrx raised the attractive
possibility that the protein performs an important function for the
intracellular life style of the malaria parasite.
Thus far, five thioredoxin related proteins have been identified
in Plasmodium falciparum, in addition to plasmoredoxin [21].
Cytosolic Trx1 is the major substrate of thioredoxin reductase.
It reduces thioredoxin-dependent peroxidases and is also capable
of reacting with peroxides, dehydroascorbate, lipoic acid, and
lipoamide directly. Trx2 (and TPx2) were shown to be
mitochondrial [22]. Trx2 also displays general disulfide reducing
activity and serves as electron donor for thioredoxin peroxidises
and GSSG. Trx3, which also carries a targeting sequence, has
been shown to be redox active and reducible by PfTrxR. In
addition, two thioredoxin-like proteins, Tlp1, which might
Figure 3. Depletion of PbPlrx reveals only weak alterations in
gene expression of redox proteins. Gene transcript levels were
measured by quantitative real-time RT-PCR. Cycle threshold and
reaction efficiency of both the target gene and the reference gene
(seryl-tRNA synthetase) were considered. The regulation of a target
gene is reported as increase in comparison to the WT control
population. Values represent mean values of three independent
experiments. TPx-1: 2-Cys Peroxiredoxin, Trx1: Thioredoxin, TrxR:
Thioredoxin Reductase, GR: Glutathione Reductase, Grx1: Glutaredoxin,
RR: Ribonucleotide reductase.
doi:10.1371/journal.pone.0002474.g003
Table 2. Loss of Plrx function does not impair Plasmodium life cycle progression
sporozoites prepatency(days)
e
Parasite Infectivity
a midgut
b salivary gland
c liver stages
d after i.v. injection by bite
Plrx(-)
f 74.1% (69.7%) 17,100 (627,200) 6,700 (63,100) 344 (61.4) 12/12 (d. 3.7) 10/10 (d. 5.7)
WT 88.8% (61.8%) 13,900 (610,300) 16,300 (63,600) N/D 8/8 (d. 3.8) 8/8 (d. 5.5)
aPercentage of mosquitoes that contain oocysts at day 11–13 post-feeding.
bMidgut-associated sporozoites per infected mosquito at day 12–14 post-feeding.
cSalivary gland-associated sporozoites per infected mosquito at day 17–19 post-feeding.
dLiver stages are mature exo-erythrocytic forms visualized 48 hours after incubation of 10,000 salivary gland sporozoites with subconfluent cultured hepatocytes.
ePrepatent period is the time until the first detection of an erythrocytic stage parasite in Giemsa-stained blood smears after intravenous injection of 10,000 salivary
gland sporozoites (i.v.) or by bites of 5–10 infected mosquitoes.
fFour independent Plrx(-) clones (# 1,2,5, and 7) were fed. Shown are the average values from these phenotypically indistinguishable clones.
N/D, not done.
doi:10.1371/journal.pone.0002474.t002
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Plasmodium falciparum and might exhibit partially overlapping
functions with classical thioredoxins.
An explanation for the non-vital role of Plrx in malarial parasites
might thus be redundancy in the function of the multiple members
of the thioredoxin superfamily. There is precedence from other
systems. For instance, the bacterial cytoplasm typically contains
two thioredoxins, thioredoxin 1 (trxA) and thioredoxin 2 (trxC), as
well as the glutaredoxin system comprising glutaredoxins 1 to 3
(grxA-C) [23,24]. Out of these proteins three (trxA, trxC, and grxA)
are able to reduce ribonucleotide reductase. Importantly, null
mutants lacking any of these genes are viable [23,25], whereas the
corresponding E. coli triple knockout is not [26]. The combined
vital role of these complementary bacterial redox proteins is best
explained by their overlapping functions [27]. Therefore, in E. coli
the presence of any one of these oxidoreductases is sufficient for
survival [26]. Another example is found in Saccharomyces cerevisiae
that encodes two cytoplasmic glutaredoxins (Grx1/2) [24,28,29]
and two thioredoxins (Trx1 and Trx2) [30]. In analogy to bacteria,
only a quadruple yeast mutant is non-viable, and a single
glutaredoxin or thioredoxin is able to restore viability [31].
However, strains deleted for glutaredoxins display altered
sensitivity when exposed to various reactive oxygen species
[28,29]. In addition, the Trx double knockout displays a profound
cell cycle defect, resulting in a prolonged S and a shortened G1
phase [30]. This effect again is presumably based on the inefficient
ribonucleotide reduction, which results in insufficient supply of
deoxyribonucleotides, a rate-limiting step in DNA synthesis. Due
to advanced reverse genetic tools in yeast and E. coli, multiple
knockouts of the GSH, glutaredoxin and thioredoxin pathways
could be generated [26,28–30] that established the overlapping
nature of the two systems and provided crucial insight into the
cellular responses to oxidative and reductive stress.
Currently, these genetic tools are not available for P. berghei.I t
will however be interesting to test in the future which redox-active
proteins functionally overlap with Plrx in the malaria parasite.
Plasmoredoxin may still fulfill specific and important functions in
the cell in concert with other members of the thioredoxin
superfamiliy that are not readily revealed under normal in vivo
growth conditions. Under more pronounced stress conditions and
in certain parasite stages these specific functions of plasmoredoxin
might become evident. However, because of the non-vital role and
the likelihood of major functional redundancy in Plasmodium redox
defence and ribonucleotide reduction, Plrx can largely be excluded
as a valid target for antimalarial intervention strategies. We
propose that target validation by reverse genetics in the rodent
malaria model parasites is an indispensable requirement for
preclinical drug development.
Materials and Methods
Experimental animals
Sprague-Dawley rats, NMRI mice and C57bl/6 mice were
obtained from Charles Rivers Laboratories. All animal experi-
ments were conducted in accordance with European regulations
and approved by the state authorities (Regierungspra ¨sidium
Karlsruhe).
Drugs
The following drugs were used: chloroquine diphosphate and
amodiaquine (Sigma-Aldrich, Steinheim, Germany), mefloquine-
HCl (Roche, Mannheim, Germany), artemisinin (Aldrich Chem-
ical Co., Milwaukee, Wis.) as well as methylene blue (Roth,
Karlsruhe, Germany).
Plasmoredoxin targeting vectors and P. berghei
transfection
Two independent strategies, gene disruption and gene replace-
ment, were used to disrupt the P. berghei plasmoredoxin gene using a
standard P. berghei transfection vector, which contains the mutated
Toxoplasma gondii dhfr/ts gene as a marker for positive selection with
the antifolate pyrimethamine [32]. The Plrx integration vector was
generated by combining two PCR fragments that were amplified
using the following primer pairs and P. berghei genomic DNA as
template: PbPlrxInt1 for (59-CGGGATCCCATTCTACCCAA-
AATGAAGCACCC-39; BamHI site is underlined and PbPlrxInt1
rev (59-G G ACTAGTATATATATTATTTCAAAAAAGGG-39;
SpeI site is underlined); PbPlrxInt2 for (59-GGACTAGTTGAT-
CAAACATATACAGATTATATCAATT-39; SpeI site is under-
lined) and PbPlrxInt2 rev (59-T C C CCGCGGCGATTATTTG-
ATTTGAATGTTTTGGGG-39; SacII site is underlined). For in-
tegration of the targeting vector via single cross-over the introduced
cleavage site (SpeI) was used. The Plrx replacement vector was
generated using the primers PbRep1 for (59-G G GGTACCCAG-
CATTGATAACAGTATGAACAACAGC-39; KpnI site is under-
lined) and PbRep1 rev (59-CCCAAGCTTTACGAAGAACTTAA-
CAAAGCTCATCG-39; HindIII site is underlined); PbRep2 for (59-
GGACTAGTGTTATGTTGTTGCATCCTAAACCTCAAAC-
39; SpeI site is underlined) and PbRep2 rev (59-TCCCCGCGG-
CTCGTTGGATGATTTTGAAATTGCC-39; SacII site is under-
lined). Sequence analyses confirmed the correct sequence of the
different plasmids. P. berghei transfection and positive selection was
done by the Nucleofector technology [33]. Clonal parasites were
obtained by limited dilution of single parasites into recipient NMRI
mice. To test for proper replacement of the Plrx gene, integration-
specific primer combinations, Tgfor (59-CCCGCACGGACGAA-
TCCAGATGG-39) and Plrxtestrev (59- GGAACGTTTGCTA-
CTCC-39), as well as 59testfor (59- GCCAATGTACCCATGTA-
CACAGC-39) and Tgrev (59- CCAACTCAATTTAATAGATG-
TGTTATGTG-39) were used. The resulting PCR products were
sequenced to verify the correct gene replacement and the accurate
generation of the recombinant Plrx(-) locus. To test for the presence
of residual WT parasites a Plrx-specific primer pair, Plrxstart (59-
ATGGCATGTAAAGTTGATAAAGC-39) and Plrxend (59-
CTAATTGTAGAATAAATCGAAAAATCG-39), was used. For
the control amplification a glutathione reductase-specific primer
pair, PbGRfor (59- TTGCGTAAATGTAGGTTGTGTACC-39)
and PbGRrev (59- AGTCAAGATGCTCAAACTTCCG -39), was
tested. We obtained four independent Plrx(-)REP clonal parasite
populations that were phenotypically identical. Detailed analysis was
performed with one representative clone.
Immunoblotting
Three rats were infected with WT and Plrx(-) blood stage
parasites, respectively, and cytosolic parasite proteins were extracted
using 2M Urea buffer. For immunoblot analysis, proteins were
separated on 15% polyacrylamide gels and transferred to nitrocel-
lulose membranes (Bio-Rad) by electroblotting. Plrx (21.5 kDA) was
detectedbyincubationofmembraneswitha polyclonalanti-P.berghei
Plrx antiserum (dilution 1:1,500). This antiserum was obtained by
immunization of rabbits with synthetic peptides of the N-terminal
region of Plrx (Plrx-1: CYYKNNELKKIDSSYFQDKY and Plrx-2:
CKVDKALEHSTQNEAPSK) (Eurogentec, Seraing, Belgium).
Bound antibodies were detected using peroxidase coupled anti–
rabbit and anti–mouse antibodies, to detect PbPlrx and actin,
respectively. Immunostained proteins were visualized with enhanced
chemoluminescence detection (Pierce). Recombinant P. berghei Plrx
was used as a positive control (obtained according to [12]). The anti-
Dictyostelium discoideum actin antiserum, which cross-reacts with
Plasmoredoxin in Malaria
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(Heidelberg).
Determination of IC50 values
NMRI mice were infected with P. berghei WT and Plrx(-) parasites.
Collection of infected erythrocytes was done by cardiac puncture.
Infected erythrocytes were cultured in an isotopic drug sensitivity
assay based on incorporation of radioactive [3H] hypoxanthine
(protocol kindly provided by Sergio Wittlin, Basel, Switzerland).
Briefly, serial dilutions of various drugs were prepared in 96-well
microtiter plates (Nunc). 100 ml infected red blood cells, resulting in
5% hematocrit and 1-5% parasitemia, were added per well and
incubated in hypoxanthine-free medium at 37uCi nag a sm i x t u r e
consisting of 94% N2,3 %O 2 and 3% CO2. After 16 h incubation,
0.5 mCi of [3H] hypoxanthine (Amersham Pharmacia) in 50 ml
medium was added and plates were incubated for an additional 8 h.
Parasites were harvested onto glass fiber filters (Perkin-Elmer,
Rodgau-Ju ¨gesheim,Germany), washed and dried. Radioactivity was
counted using a b-counter (Matrix 9600; Packard). The results were
recorded as counts per minute (cpm) per well at each drug
concentration and growth inhibition was expressed as percent 3H
incorporation compared with untreated controls. Fifty percent
inhibitory concentrations (IC50) were calculated from plotted data.
All experiments were done in duplicate from at least three
independent mouse infections each.
Expression profiles of Plasmodium WT and Plrx(-)
parasites using quantitative real-time RT-PCR
For qRT-PCR analyses poly(A)
+ RNA was isolated using
oligo(dT) columns (Macherey-Nagel, Du ¨ren,Germany)frommixed
blood stage of Plasmodium berghei WT and Plrx(-) lines. After a DNase
treatment, aliquots of 800 ng of each sample were reversely
transcribed to cDNA using an Abgene cDNA synthesis kit and
oligo(dT) primers (Abgene, Hamburg, Germany). The SYBR Green
Jumpstart Taq Ready Mix (Sigma, Steinheim, Germany) was
utilized for quantitative real-time PCR on Rotor-Gene 3000 Real-
Time PCR system (Corbett Research, Sydney, Australia) using the
primers listed in Table 3. Specificity of the amplification products
was confirmed by melting curve analysis; a no-template control was
added in every run. The Rotor-gene 6.0 software was used to
retrieve the real time PCR results, to analyse the data and to
determine cycle threshold values. Relative expression of target genes
were calculated based on efficiency (determined with dilution series
of each gene and the Rotor-Gene software) and Ct-values for genes
of Plrx-deficient parasites versus control WT-parasites, and
expressed in comparison to a reference gene. The relative amount
of mRNA was determined according to the Pfaffl equation [34],
using P. berghei seryl-tRNA synthetase as the reference gene. In our
experiments, each RT-PCR run was carried out in triplets of one
mRNA pool or in doublets of two different mRNA pools and the
whole series was reproduced in an independent experiment.
Plasmodium life cycle and phenotypic analysis of Plrx(-)
parasites
Anopheles stephensi mosquitoes were kept at 21uC, 80% humidity
and daily feeding on 10% sucrose. Asynchronous blood-stages of P.
berghei NK65 (WT) and Plrx(-) were maintained in NMRI mice and
checked for gametocyte formation and exflagellation of microga-
metes prior to mosquito feeding. For mosquito infection, A. stephensi
mosquitoes were allowed to bloodfeed on anesthetized mice for
15 minutes. Dissection of mosquitoes was conducted at days 10, 14
and 17 in order to determine infectivity and sporozoite numbers in
midguts and salivary glands, respectively. Gliding motility was
assessed by deposition of sporozoites onto precoated glass coverslips
and visualisation by indirect immunofluorescence using a primary
antibody against the P. berghei circumsporozoite protein (CSP) [35]
followed by detection with an Alexa Fluor 488-conjugated anti-
mouse antibody. To analyse liver stage development sporozoites
were deposited onto a semi-confluent monolayer of hepatoma cells
(HuH7) and incubated for 2 h, followed by washing and incubation
in cell culture medium. Liver stages were detected after 48 h with a
primary antibodydirected againstthe P. berghei heat shock protein70
(HSP70) [36], followed by an Alexa Fluor 488-conjugated anti-
mouse antibody. To analyse sporozoite infectivity in vivo,S p r a g u e -
Dawley rats were infected intravenously with 10,000 WT or Plrx(-)
sporozoites, respectively. Parasitemia was followed by daily exam-
ination of Giemsa-stained blood smears. The occurrence of a single
parasite marked the first day of patency.
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